Literature DB >> 10980734

Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD.

F Jessen1, W Block, F Träber, E Keller, S Flacke, A Papassotiropoulos, R Lamerichs, R Heun, H H Schild.   

Abstract

BACKGROUND: The reduction of N-acetylaspartate (NAA) detected by proton MR spectroscopy (1H-MRS) represents a robust but unspecific marker for neuronal loss or dysfunction.
OBJECTIVE: To apply 1H-MRS in two brain regions that reflect the characteristic spatial distribution of neuronal loss in AD. These regions are the medial temporal lobe (MTL), which is affected early in AD, and the primary motor and sensory cortex (central region), which is affected late in the disease and might serve as an intraindividual control region in mild to moderate disease stages.
METHODS: Twenty patients and 18 volunteers underwent 1H-MRS in both brain areas. The metabolic ratios of NAA/creatine and choline/creatine were determined. Additionally, the metabolic ratios of the MTL were divided by the ratios of the central region to assess the relative change in the MTL in individual subjects. All ratios were correlated with psychometric test scores.
RESULTS: A significant reduction of NAA/creatine and choline/creatine ratios was detected in the MTL of patients with AD. In the central region, no significant difference between the groups was found. NAA/creatine (MTL/central region) was reduced in patients with AD and showed a correlation with the Mini-Mental State Examination and the cognitive part of the Alzheimer Disease Assessment Scale scores. Choline/creatine (MTL/central region) did not show a significant difference between groups.
CONCLUSION: Assessing the distribution of NAA/creatine reduction guided by the expected neuropathologic change can improve the role of 1H-MRS in the assessment of AD. The disease severity can be monitored by relative reduction of NAA/creatine in the MTL in comparison with an intraindividual unaffected control region.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10980734     DOI: 10.1212/wnl.55.5.684

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  32 in total

1.  Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy.

Authors:  Yue-Ming Jiang; Li-Ling Long; Xia-Yan Zhu; Hong Zheng; Xue Fu; Shi-Yan Ou; Dong-Lu Wei; Hai-Lin Zhou; Wei Zheng
Journal:  Toxicol Lett       Date:  2008-07-23       Impact factor: 4.372

Review 2.  Quantitative magnetic resonance techniques as surrogate markers of Alzheimer's disease.

Authors:  Kejal Kantarci; Clifford R Jack
Journal:  NeuroRx       Date:  2004-04

3.  A multicenter reproducibility study of single-voxel 1H-MRS of the medial temporal lobe.

Authors:  Frank Träber; Wolfgang Block; Nikolaus Freymann; Okan Gür; Thomas Kucinski; Thilo Hammen; Gabriele Ende; Ulrich Pilatus; Harald Hampel; Hans H Schild; Reinhard Heun; Frank Jessen
Journal:  Eur Radiol       Date:  2006-01-17       Impact factor: 5.315

4.  Quantitative multivoxel proton MR spectroscopy study of brain metabolites in patients with amnestic mild cognitive impairment: a pilot study.

Authors:  Zhong-Xian Yang; Shan-Shan Huo; Xiao-Fang Cheng; Zhi-Feng Xu; Zhen Cao; Jie-Xia Zeng; Ye-Yu Xiao; Ke-Zeng You; Wei Chen; Yan-Yan Liu; Ren-Hua Wu
Journal:  Neuroradiology       Date:  2011-07-08       Impact factor: 2.804

Review 5.  Various MRS application tools for Alzheimer disease and mild cognitive impairment.

Authors:  F Gao; P B Barker
Journal:  AJNR Am J Neuroradiol       Date:  2014-04-17       Impact factor: 3.825

6.  Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD.

Authors:  N Schuff; A A Capizzano; A T Du; D L Amend; J O'Neill; D Norman; J Kramer; W Jagust; B Miller; O M Wolkowitz; K Yaffe; M W Weiner
Journal:  Neurology       Date:  2002-03-26       Impact factor: 9.910

Review 7.  Magnetic resonance imaging and magnetic resonance spectroscopy in dementias.

Authors:  Y Y Hsu; A T Du; N Schuff; M W Weiner
Journal:  J Geriatr Psychiatry Neurol       Date:  2001       Impact factor: 2.680

8.  Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements.

Authors:  Kejal Kantarci; David S Knopman; Dennis W Dickson; Joseph E Parisi; Jennifer L Whitwell; Stephen D Weigand; Keith A Josephs; Bradley F Boeve; Ronald C Petersen; Clifford R Jack
Journal:  Radiology       Date:  2008-07       Impact factor: 11.105

Review 9.  Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease.

Authors:  Evelin L Schaeffer; Orestes V Forlenza; Wagner F Gattaz
Journal:  Psychopharmacology (Berl)       Date:  2008-10-14       Impact factor: 4.530

Review 10.  Proton MRS in mild cognitive impairment.

Authors:  Kejal Kantarci
Journal:  J Magn Reson Imaging       Date:  2013-04       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.